Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4238 - Clinical and Analytical Accuracy of a 523 Gene Panel Next-Generation Sequencing (NGS) Assay on Formalin-Fixed Paraffin-Embedded (FFPE) Solid Tumor Samples

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Presenters

Ina Deras

Citation

Annals of Oncology (2019) 30 (suppl_5): v574-v584. 10.1093/annonc/mdz257

Authors

I. Deras, T. Du, C. Zhao, N. Haseley, A. Yazdanparast, T. Jiang, A. Mentzer, A. Purdy, B. Crain, C. Echegaray, D. Lee, J. Lee, J. Silhavy, K. O'Brien, R. Vijayaraghavan, R. Garcia, R. Haigis, T. Pawlowski, J. Dockter

Author affiliations

  • Clinical Genomics, Illumina, 92122 - San Diego/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4238

Background

We developed a tumor-only NGS assay (TruSight assay), a 523 gene panel covering 1.94 megabases (Mb), that detects small DNA variants, provides a microsatellite instability (MSI) score, and estimates tumor mutational burden (TMB) from FFPE tissue DNA. We demonstrate the assay’s ability to detect a variety of biomarkers compared to various orthogonal methods across a range of solid tumor tissues. We also demonstrate accuracy in determining TMB status, using a clinically based cutoff, in non-small cell lung cancer (NSCLC) FFPE samples compared to tumor-normal whole exome sequencing (WES).

Methods

The study used ∼400 paired tumor-normal FFPE samples from 7 tumor types, including 240 NSCLC. Tumor samples were tested using the verified assay workflow including software analysis. All tumor and normal FFPE were tested with internal WES (with an independent analysis pipeline) and most with a commercial MSI PCR kit (Promega). The TMB score threshold, in mutations (mut)/Mb, was established for the TruSight assay and WES using 119 independent NSCLC FFPE samples and correlated with an external published cutoff.

Results

Across different tumor types, there was high concordance in small DNA variant calling (>95% positive percent agreement [PPA], >99% negative percent agreement [NPA]) between the TruSight assay and WES. For MSI, >95% PPA and 100% NPA were achieved between the TruSight assay and MSI-PCR. TMB scores from the TruSight assay showed good correlation with WES TMB scores (R2 >0.95 on linear regression). Among the NSCLC samples, TMB scores (range 0 – 184.6 mut/Mb) determined by the TruSight assay correlated well with WES (R2 0.94). Using cutoffs of 12.3 and 8.3 mut/Mb (TruSight assay and WES, respectively) to assign TMB High and Low statuses, overall percent agreement (OPA) was 85%.

Conclusions

The tumor-only TruSight assay showed high accuracy in detecting biomarkers across a range of solid tumors. The assay showed a good correlation in TMB score and agreement in TMB status with tumor-normal WES in a collection of NSCLC samples.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Illumina.

Disclosure

I. Deras: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina; Shareholder / Stockholder / Stock options: Bristol-Myers Squibb. T. Du: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina. C. Zhao: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina. N. Haseley: Full / Part-time employment: Illumina. A. Yazdanparast: Full / Part-time employment: Illumina. T. Jiang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina; Shareholder / Stockholder / Stock options: Bristol-Myers Squibb. A. Mentzer: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina. A. Purdy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina; Shareholder / Stockholder / Stock options: Bristol-Myers Squibb. B. Crain: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina. C. Echegaray: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina. D. Lee: Full / Part-time employment: Illumina. J. Lee: Full / Part-time employment: Illumina. J. Silhavy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina. K. O’Brien: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina. R. Vijayaraghavan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina. R. Garcia: Full / Part-time employment: Illumina. R. Haigis: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina. T. Pawlowski: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina. J. Dockter: Shareholder / Stockholder / Stock options, Full / Part-time employment: Illumina.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.